FDA rejects Valeant's nail fungus treatment; Eleven Bio nabs collaboration pact with ThromboGenics; EC approves Stribild;

@FierceBiotech: Trending this weekend: Top 10 Biotech CEO Pay Packages of 2012. Feature | Follow @FierceBiotech

@JohnCFierce: From earlier today: AstraZeneca scoops up PhIII cardio drug in $443M Omthera buyout (did AZ pay too much?) Story | Follow @JohnCFierce

> The FDA has rejected Valeant Pharmaceutical's ($VRX) nail fungus therapy efinaconazole, citing questions on the container closure apparatus it uses. Valeant says the questions can all be handled in a timely fashion and expects to get back to the FDA as soon as possible. Story

> Cambridge, MA-based Eleven Biotherapeutics has struck a deal to collaborate with ThromboGenics NV on a protein therapeutic for ophthalmic disease. The collaboration aims to employ Eleven's proprietary AMP-Rx protein design technology to optimize a therapeutic of ThromboGenics' selection.  The biologic will be designed to treat back-of-the-eye diseases such as diabetic macular edema. None of the terms were released. Release

> The European Commission has approved Gilead's ($GILD) HIV drug Stribild. Story

> Shares of ReNeuron jumped on interim data for its stem cell therapy for stroke damage. Report

> Helsinn has decided to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea. Release

Medical Device News

@FierceMedDev: Roche launches DNA kit amid applied science shake-up. Article | Follow @FierceMedDev

 @DamianFierce: In case you missed it Monday, Valeant is buying Bausch + Lomb for $8.7B. Report | Follow @DamianFierce

> Medical device firms still passing tax on to hospitals, group says. Item

> Sluggish FDA device approvals frustrate cardiologists. Report

> Paris, je stent: Fierce's 2013 EuroPCR coverage. More

> FDA sticks 'deadly' tag on Cook's stent recall. News

Pharma News

@FiercePharma: India's Sun Pharma beats on profits, with 31% revenue hike to about $550M. More | Follow @FiercePharma

@EricPFierce: U.S. arrests 2 Pakistani men for selling controlled substances via the Internet. Interpol tracks them to London. Report | Follow @EricPFierce

> Feds subpoena Forest Labs in Tudorza Pressair investigation. Story

> Drugmakers to reap $115B in sales as Obamacare rolls on, study finds. Report

> ISTA excluded from Medicare in $33.5M off-label settlement. Article

Pharma Manufacturing News

> India takes another step to meet looming EU API rules. Story

> FDA tracking down new outbreak tied to compounded drug. More

> U.S. holds two Pakistani men for Internet sales of controlled substances. Report

> Indian regulators unsure how to react to USFDA actions. Article

CRO News

> Parexel expands eClinical presence in China. Article

> India amps up clinical trial consent regulations. Report

> Corgenix inks cancer deal with Lilly. More

> Nordion sells off drug unit for $200M, focuses on contracting. Story

Biotech IT News

> Boehringer VP impressed by wireless pill bottle. Item

> Treato sees success for Biogen in social media buzz. Article

> Genentech asks iPad gamers to save San Fran from mutant cheese. More

> Chinese trial data hackers reportedly active again. Report

Biotech Research News

 @EmilyMFierce: Universal flu vaccine effective in preclinical studies. More | Follow @EmilyMFierce

> Stem cell cloning study contained errors. Story

> Stabilizing a gene reverses schizophrenia in mice. Report

> New study refutes Targretin claim for treatment of Alzheimer's. Article

And Finally… In a new report in The Lancet, investigators confirm that several of the new bird flu cases seen in China recently have proven to be resistant to Tamiflu. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.